Sai Parenterals Secures Equity Investment from Marquee Investors

The fresh capital will support the company’s international expansion plans, acquisition of high-potential assets, and enhancement of its manufacturing infrastructure as it moves towards becoming a global pharma player.

Hyderabad-based pharmaceutical company Sai Parenterals has successfully raised USD 5.82 million (INR 50 Cr) in an equity investment round backed by marquee investors.

The fresh capital will support the company’s international expansion plans, acquisition of high-potential assets, and enhancement of its manufacturing infrastructure as it moves towards becoming a global pharma player.

The round was led by Samarsh Capital, Vyom Partners, and funds associated with Blue Lotus Capital.

“We are working diligently to build a world-class pharmaceutical company that adheres to the highest global standards and practices. This equity infusion will allow us to acquire high-potential international assets and intellectual property in regulated markets, expand our product portfolio and geographical presence, and enhance our manufacturing capabilities. We are honoured by the confidence of such professional investors in our company’s strategy and future,” said Anil Karusala, Managing Director, Sai Parenterals.

Sandeep Shenoy, Managing Partner, Samarsh Capital, remarked, “Our investment in Sai Parenterals reflects our confidence in its solid fundamentals, scalable model, and potential to achieve strong growth in the global pharmaceutical sector. Under the visionary leadership of Anil, we expect Sai Parenterals to emerge as a leader in its segment.”

Prashant Khanchandani of Vyom Partners added, “Sai Parenterals’ leadership has demonstrated a future-ready approach by building a capital-efficient and scalable business. Their success in integrating acquisitions and subsequently expanding internationally in the formulations and CDMO segments is commendable.”

Harikrishnan S, Managing Partner, Blue Lotus Capital, said, "Our second round of investment reflects our strong conviction in Sai Parenterals’ science-driven culture and scalable manufacturing platform. By partnering with a formidable player in sterile injectables, we aim to accelerate affordable, high-quality healthcare solutions for global markets while delivering sustained value to the investors.”

Sai Parenteral operates across the pharmaceutical value chain with two strategic verticals, Branded Export Formulations and Contract Development & Manufacturing Organization (CDMO) Services.

The company’s product portfolio spans injectables, oral solids, liquids, and topical preparations, supported by five manufacturing facilities in India, with approvals from TGA Australia, GCC, SAPRA, and WHO GMP.

Stay tuned for more such updates on Digital Health News